- Home
- KROS vs PEO Comparison
KROS vs PEO Comparison
Compare KROS & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- PEO
- Stock Information
- Founded
- KROS 2015
- PEO 1929
- Country
- KROS United States
- PEO United States
- Employees
- KROS N/A
- PEO N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- PEO Finance/Investors Services
- Sector
- KROS Health Care
- PEO Finance
- Exchange
- KROS Nasdaq
- PEO Nasdaq
- Market Cap
- KROS 565.0M
- PEO 569.6M
- IPO Year
- KROS 2020
- PEO N/A
- Fundamental
- Price
- KROS $14.52
- PEO $20.90
- Analyst Decision
- KROS Buy
- PEO
- Analyst Count
- KROS 14
- PEO 0
- Target Price
- KROS $20.56
- PEO N/A
- AVG Volume (30 Days)
- KROS 413.8K
- PEO 35.4K
- Earning Date
- KROS 08-06-2025
- PEO 01-01-0001
- Dividend Yield
- KROS N/A
- PEO 5.93%
- EPS Growth
- KROS N/A
- PEO N/A
- EPS
- KROS 0.47
- PEO N/A
- Revenue
- KROS $232,844,000.00
- PEO N/A
- Revenue This Year
- KROS $5,390.70
- PEO N/A
- Revenue Next Year
- KROS N/A
- PEO N/A
- P/E Ratio
- KROS $31.11
- PEO N/A
- Revenue Growth
- KROS 85820.30
- PEO N/A
- 52 Week Low
- KROS $9.12
- PEO $19.22
- 52 Week High
- KROS $72.37
- PEO $23.80
- Technical
- Relative Strength Index (RSI)
- KROS 56.39
- PEO 40.42
- Support Level
- KROS $13.78
- PEO $20.57
- Resistance Level
- KROS $14.67
- PEO $21.14
- Average True Range (ATR)
- KROS 0.45
- PEO 0.29
- MACD
- KROS 0.03
- PEO -0.03
- Stochastic Oscillator
- KROS 82.76
- PEO 27.50
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.